- Home
- DNTH vs DGICA Comparison
DNTH vs DGICA Comparison
Compare DNTH & DGICA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNTH
- DGICA
- Stock Information
- Founded
- DNTH 2015
- DGICA 1986
- Country
- DNTH United States
- DGICA United States
- Employees
- DNTH N/A
- DGICA N/A
- Industry
- DNTH Biotechnology: Pharmaceutical Preparations
- DGICA Property-Casualty Insurers
- Sector
- DNTH Health Care
- DGICA Finance
- Exchange
- DNTH Nasdaq
- DGICA Nasdaq
- Market Cap
- DNTH 606.2M
- DGICA 683.3M
- IPO Year
- DNTH N/A
- DGICA N/A
- Fundamental
- Price
- DNTH $21.50
- DGICA $17.36
- Analyst Decision
- DNTH Strong Buy
- DGICA Hold
- Analyst Count
- DNTH 8
- DGICA 1
- Target Price
- DNTH $53.00
- DGICA $18.00
- AVG Volume (30 Days)
- DNTH 387.8K
- DGICA 171.9K
- Earning Date
- DNTH 08-07-2025
- DGICA 07-24-2025
- Dividend Yield
- DNTH N/A
- DGICA 4.20%
- EPS Growth
- DNTH N/A
- DGICA 965.80
- EPS
- DNTH N/A
- DGICA 2.34
- Revenue
- DNTH $6,524,000.00
- DGICA $993,645,050.00
- Revenue This Year
- DNTH N/A
- DGICA $3.27
- Revenue Next Year
- DNTH N/A
- DGICA $5.19
- P/E Ratio
- DNTH N/A
- DGICA $7.42
- Revenue Growth
- DNTH 102.36
- DGICA 3.36
- 52 Week Low
- DNTH $13.37
- DGICA $13.35
- 52 Week High
- DNTH $32.27
- DGICA $21.12
- Technical
- Relative Strength Index (RSI)
- DNTH 61.73
- DGICA 31.12
- Support Level
- DNTH $19.90
- DGICA $18.17
- Resistance Level
- DNTH $22.49
- DGICA $18.69
- Average True Range (ATR)
- DNTH 1.43
- DGICA 0.47
- MACD
- DNTH 0.22
- DGICA -0.11
- Stochastic Oscillator
- DNTH 64.11
- DGICA 9.31
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
About DGICA Donegal Group Inc.
Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.